This is the
talk page for discussing improvements to the
Sinopharm BIBP COVID-19 vaccine article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives: Index, 1Auto-archiving period: 90 days |
The
contentious topics procedure applies to this page. This page is related to
COVID-19, broadly construed, which has been
designated as a contentious topic. Editors who repeatedly or seriously fail to adhere to the purpose of Wikipedia, any expected standards of behaviour, or any normal editorial process may be blocked or restricted by an administrator. Editors are advised to familiarise themselves with the contentious topics procedures before editing this page. |
This article is written in British English, which has its own spelling conventions (colour, travelled, centre, defence, artefact, analyse) and some terms that are used in it may be different or absent from other varieties of English. According to the relevant style guide, this should not be changed without broad consensus. |
This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to multiple WikiProjects. | |||||||||||||||||||||||||||||||||||||||||
|
It is requested that a biochemistry diagram or diagrams be
included in this article to
improve its quality. Specific illustrations, plots or diagrams can be requested at the
Graphic Lab. For more information, refer to discussion on this page and/or the listing at Wikipedia:Requested images. |
It is requested that a logo be
included in this article to
improve its quality. For more information, refer to discussion on this page and/or the listing at Wikipedia:Requested images. The Free Image Search Tool may be able to locate suitable images on Flickr and other web sites. |
Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Sinopharm BIBP COVID-19 vaccine.
|
Daily pageviews of this article
A graph should have been displayed here but
graphs are temporarily disabled. Until they are enabled again, visit the interactive graph at
pageviews.wmcloud.org |
On 12 August 2021, it was proposed that this article be moved to Sinopharm COVID-19 vaccine BIBP. The result of the discussion was Moved to Sinopharm BIBP COVID-19 vaccine and Sinopharm WIBP COVID-19 vaccine. |
The result of the move request was: Moved to Sinopharm BIBP COVID-19 vaccine and Sinopharm WIBP COVID-19 vaccine. per discussion consensus and consistency policies. ( non-admin closure) — Shibbolethink ( ♔ ♕) 15:22, 26 August 2021 (UTC)
– Following WP:MEDTITLE and WP:MEDORG, the World Health Organization seems to prefer Sinopharm BIBP [1] and Sinopharm WIBP [2] over BBIBP/BBIBP-CorV and WIBP-CorV. English-speaking media mostly uses Sinopharm vaccine, ignoring the existence of WIBP-CorV. If this request is approved, then naturally WIBP-CorV would be moved to Sinopharm COVID-19 vaccine WIBP for consistency. Fernando Trebien ( talk) 20:27, 12 August 2021 (UTC) — Relisting. D🐶ggy54321 ( let's chat!) 21:16, 19 August 2021 (UTC)
This
edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request. |
change "emergency used authorization" to "emergency use authorization" 2001:EE0:1A1:5484:7280:4C94:88BE:3F67 ( talk) 18:14, 10 September 2021 (UTC)
Authorizations . . . On 5 May 2021, EMA's human medicines committee (CHMP) has started a rolling review of the vaccine. The EU applicant for this medicine is the Italian company Life'On S.r.l.[84]
There is no ongoing EMA Rolling Review for Sinopharm BIBP-CorV. The information stated in literature reference 84 relates to the vaccine CoronaVac from SinoVac. -- Benedikt.ebli ( talk) 19:38, 2 February 2022 (UTC)
[In 2021, a cross-sectional study was conducted on 74 patients with various types of cancers in Iran. These patients had received two doses of the Sinopharm vaccine. The study measured levels of SARS-CoV-2 neutralizing antibodies, Anti-RBD, and Anti-Spike IgG for 4 to 6 weeks after the second vaccine dose. Positive neutralizing antibody status was observed in 41 individuals (55.4%). Additionally, 31 people (41.9%) tested positive for antibodies against RDB antigen, and 20 people (27%) had antibodies against Spike virus antigen. ref: https://jmums.mazums.ac.ir/article-1-20689-en.html] Reza nava ( talk) 16:40, 2 May 2024 (UTC)
This is the
talk page for discussing improvements to the
Sinopharm BIBP COVID-19 vaccine article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives: Index, 1Auto-archiving period: 90 days |
The
contentious topics procedure applies to this page. This page is related to
COVID-19, broadly construed, which has been
designated as a contentious topic. Editors who repeatedly or seriously fail to adhere to the purpose of Wikipedia, any expected standards of behaviour, or any normal editorial process may be blocked or restricted by an administrator. Editors are advised to familiarise themselves with the contentious topics procedures before editing this page. |
This article is written in British English, which has its own spelling conventions (colour, travelled, centre, defence, artefact, analyse) and some terms that are used in it may be different or absent from other varieties of English. According to the relevant style guide, this should not be changed without broad consensus. |
This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to multiple WikiProjects. | |||||||||||||||||||||||||||||||||||||||||
|
It is requested that a biochemistry diagram or diagrams be
included in this article to
improve its quality. Specific illustrations, plots or diagrams can be requested at the
Graphic Lab. For more information, refer to discussion on this page and/or the listing at Wikipedia:Requested images. |
It is requested that a logo be
included in this article to
improve its quality. For more information, refer to discussion on this page and/or the listing at Wikipedia:Requested images. The Free Image Search Tool may be able to locate suitable images on Flickr and other web sites. |
Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Sinopharm BIBP COVID-19 vaccine.
|
Daily pageviews of this article
A graph should have been displayed here but
graphs are temporarily disabled. Until they are enabled again, visit the interactive graph at
pageviews.wmcloud.org |
On 12 August 2021, it was proposed that this article be moved to Sinopharm COVID-19 vaccine BIBP. The result of the discussion was Moved to Sinopharm BIBP COVID-19 vaccine and Sinopharm WIBP COVID-19 vaccine. |
The result of the move request was: Moved to Sinopharm BIBP COVID-19 vaccine and Sinopharm WIBP COVID-19 vaccine. per discussion consensus and consistency policies. ( non-admin closure) — Shibbolethink ( ♔ ♕) 15:22, 26 August 2021 (UTC)
– Following WP:MEDTITLE and WP:MEDORG, the World Health Organization seems to prefer Sinopharm BIBP [1] and Sinopharm WIBP [2] over BBIBP/BBIBP-CorV and WIBP-CorV. English-speaking media mostly uses Sinopharm vaccine, ignoring the existence of WIBP-CorV. If this request is approved, then naturally WIBP-CorV would be moved to Sinopharm COVID-19 vaccine WIBP for consistency. Fernando Trebien ( talk) 20:27, 12 August 2021 (UTC) — Relisting. D🐶ggy54321 ( let's chat!) 21:16, 19 August 2021 (UTC)
This
edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request. |
change "emergency used authorization" to "emergency use authorization" 2001:EE0:1A1:5484:7280:4C94:88BE:3F67 ( talk) 18:14, 10 September 2021 (UTC)
Authorizations . . . On 5 May 2021, EMA's human medicines committee (CHMP) has started a rolling review of the vaccine. The EU applicant for this medicine is the Italian company Life'On S.r.l.[84]
There is no ongoing EMA Rolling Review for Sinopharm BIBP-CorV. The information stated in literature reference 84 relates to the vaccine CoronaVac from SinoVac. -- Benedikt.ebli ( talk) 19:38, 2 February 2022 (UTC)
[In 2021, a cross-sectional study was conducted on 74 patients with various types of cancers in Iran. These patients had received two doses of the Sinopharm vaccine. The study measured levels of SARS-CoV-2 neutralizing antibodies, Anti-RBD, and Anti-Spike IgG for 4 to 6 weeks after the second vaccine dose. Positive neutralizing antibody status was observed in 41 individuals (55.4%). Additionally, 31 people (41.9%) tested positive for antibodies against RDB antigen, and 20 people (27%) had antibodies against Spike virus antigen. ref: https://jmums.mazums.ac.ir/article-1-20689-en.html] Reza nava ( talk) 16:40, 2 May 2024 (UTC)